Healthcare Gilead analysis shows remdesivir reduced coronavirus death risk, more studies needed Updated : July 11, 2020 09:25 AM IST Gilead's late-stage study evaluated the safety and efficacy of five-day and 10-day dosing durations of remdesivir in hospitalised patients. The mortality rate for patients treated with remdesivir in the analysis was 7.6 percent at Day 14, compared with 12.5 percent among patients not on remdesivir. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.